October 18
Phase III trial results of novel triple combination pill for hypertension published in The Lancet
Read more
Brandon BioCatalyst is the largest life science investment fund in Australia and New Zealand. We are a unique collaboration between major Australian superannuation funds, CSL, the Australian and New Zealand governments, Australian state governments and more than 50 leading medical research institutes and research hospitals.
Learn more about who we areA clinical stage company developing treatment for hot flashes in cancer survivors undergoing endocrine therapy
View ProjectDeveloping disease-modifying mitochondrial therapeutics for neurodegenerative disorders
View ProjectDeveloping the next generation of CAR-T cell therapies to treat solid cancers
View ProjectCombining non-opioid analgesics and biopolymers to deliver weeks of localised pain management
View ProjectUnlocking the potential of N-myristoyltransferase (NMT) to develop precision medicines for a range of diseases including cancer and viral infections
View ProjectGlyscend is developing novel non-absorbable polymers that are orally-delivered for the treatment of Type 2 Diabetes.
View ProjectMaking translatable molecular discoveries.
ViewQIMR Berghofer is one of Australia’s most successful medical research institutes. The Institute was established 70 years ago by the Queensland Government and has a rich history of scientific discoveries and translational medical research.
ViewBrandon BioCatalyst is innovation in action: We provide a path for taking medical science from conception into the real world.
Our Venture capital model is unique. We don’t simply provide investment, we partner with entrepreneurs to create businesses, run companies and everything necessary to ensure our investments succeed.
Learn morePhase III trial results of novel triple combination pill for hypertension published in The Lancet
Read moreCUREator+ Opens Second Funding Round for Australian Biotech and Healthtech Innovators
Read moreCerta Therapeutics Announces International Non-Proprietary Name for its First-in-class GPR68 Inhibitor Asengeprast (FT011)
Read moreBrandon BioCatalyst’s CUREator Incubator Boosts Preclinical and Health Security Biotech Innovations with $1.865m in funding.
Read more